(1→3)-β-D-Glucan in Cereobrospinal Fluid is a Surrogate Marker for Detection and Therapeutic Response of Hematogenous Candida Meningoencephalitis

The treatment of invasive fungal diseases constitutes a significant unmet medical need. There are relatively few antifungal agents in clinical development and a paucity of novel targets. Morbidity and mortality remain high and clinical outcomes are compromised by submaximal efficacy, emergence of drug resistance and drug-related toxicity. Thus, new antifungal agents are urgently required. A deep understanding of exposure-response relationships underpins the development of safe and effective clinical regimens of any therapeutic agent. Pharmacokinetics (PK) and pharmacodynamics (PD) is increasingly recognized as a vital tool in the development of new antimicrobial agents and maximizes the probability that the right dose will be studied the first time. There is currently no information or agreement as to what constitutes an adequate PK/PD package for the development of a new antifungal agent. This review provides a summary of the achievements of antifungal PK/PD for the treatment of invasive candidiasis, invasive aspergillosis and cryptococcal meningoencephalitis, and outlines the necessary components of a PK/PD package for a new antifungal agent. Such information is critical for the accelerated and efficient development of new agents and enables improved clinical outcomes to be secured.

show abstract

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality

Hope

Drusano

Rex

2016

J. Antimicrob. Chemother.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

(1→3)-β-D-Glucan in Cereobrospinal Fluid is a Surrogate Marker for Detection and Therapeutic Response of Hematogenous Candida Meningoencephalitis

Cited by 1 publication

References 0 publications

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality

Contact Info

Product

Resources

About